Peringatan Keamanan

There is limited information on overdose. Up to 4000 mg, which is approximately seven times the recommended dose of the drug, was administered in clinical trials. There is no known specific antidote for imdevimab overdose so treatment of overdose should involve general supportive measures.L39135

Imdevimab

DB15940

biotech approved experimental

Deskripsi

Imdevimab is a monoclonal antibody combined with casirivimab in Regeneron's antibody cocktail known as REGEN-COV2 for the treatment of COVID-19.L23539 This drug is a combination of antibodies derived from humanized VelocImmune® mice in addition to blood samples from patients who have recovered from COVID-19.A224429 These antibodies have been formulated to bind to multiple locations on the SARS-COV-2 spike protein, preventing viral escape.A221495

On November 21, 2020, the FDA authorized emergency approval of REGN-COV2 to treat mild to moderate COVID-19 in patients aged 12 years and older. Casirivimab and imdevimab are investigational recombinant human IgG1 monoclonal antibodies that, at this time, are not officially approved by the FDA. They are reserved for Emergency Use Authorization (EUA) only.L23524 In November 2021, the same indication was approved by the EMA.L39130,L39135

Full safety and efficacy data on imdevimab are not yet available, and further evaluation of this investigational therapy will continue.L23529,L23539,L14303

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

372 Data
Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Imdevimab.
Chlorotrianisene Chlorotrianisene may increase the thrombogenic activities of Imdevimab.
Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Imdevimab.
Estrone Estrone may increase the thrombogenic activities of Imdevimab.
Estradiol Estradiol may increase the thrombogenic activities of Imdevimab.
Dienestrol Dienestrol may increase the thrombogenic activities of Imdevimab.
Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Imdevimab.
Mestranol Mestranol may increase the thrombogenic activities of Imdevimab.
Estriol Estriol may increase the thrombogenic activities of Imdevimab.
Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Imdevimab.
Quinestrol Quinestrol may increase the thrombogenic activities of Imdevimab.
Hexestrol Hexestrol may increase the thrombogenic activities of Imdevimab.
Tibolone Tibolone may increase the thrombogenic activities of Imdevimab.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Imdevimab.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Imdevimab.
Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Imdevimab.
Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Imdevimab.
Zeranol Zeranol may increase the thrombogenic activities of Imdevimab.
Equol Equol may increase the thrombogenic activities of Imdevimab.
Estetrol Estetrol may increase the thrombogenic activities of Imdevimab.
Promestriene Promestriene may increase the thrombogenic activities of Imdevimab.
Methallenestril Methallenestril may increase the thrombogenic activities of Imdevimab.
Epimestrol Epimestrol may increase the thrombogenic activities of Imdevimab.
Moxestrol Moxestrol may increase the thrombogenic activities of Imdevimab.
Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Imdevimab.
Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Imdevimab.
Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Imdevimab.
Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Imdevimab.
Biochanin A Biochanin A may increase the thrombogenic activities of Imdevimab.
Formononetin Formononetin may increase the thrombogenic activities of Imdevimab.
Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Imdevimab.
Human immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Imdevimab.
Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Imdevimab.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Imdevimab.
Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Imdevimab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Imdevimab.
Indium In-111 satumomab pendetide The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Imdevimab.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Imdevimab.
Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab is combined with Imdevimab.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Imdevimab.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Imdevimab.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Imdevimab.
Digoxin Immune Fab (Ovine) The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Imdevimab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Imdevimab.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Imdevimab.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Imdevimab.
Capromab pendetide The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Imdevimab.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Imdevimab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Imdevimab.
Natalizumab The risk or severity of adverse effects can be increased when Natalizumab is combined with Imdevimab.
Palivizumab The risk or severity of adverse effects can be increased when Palivizumab is combined with Imdevimab.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Imdevimab.
Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Imdevimab.
Technetium Tc-99m arcitumomab The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Imdevimab.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Imdevimab.
Panitumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Imdevimab.
Ranibizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Imdevimab.
Galiximab The risk or severity of adverse effects can be increased when Galiximab is combined with Imdevimab.
Pexelizumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Imdevimab.
Afelimomab The risk or severity of adverse effects can be increased when Afelimomab is combined with Imdevimab.
Epratuzumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Imdevimab.
Bectumomab The risk or severity of adverse effects can be increased when Bectumomab is combined with Imdevimab.
Oregovomab The risk or severity of adverse effects can be increased when Oregovomab is combined with Imdevimab.
IGN311 The risk or severity of adverse effects can be increased when IGN311 is combined with Imdevimab.
Adecatumumab The risk or severity of adverse effects can be increased when Adecatumumab is combined with Imdevimab.
Labetuzumab The risk or severity of adverse effects can be increased when Labetuzumab is combined with Imdevimab.
Matuzumab The risk or severity of adverse effects can be increased when Matuzumab is combined with Imdevimab.
Fontolizumab The risk or severity of adverse effects can be increased when Fontolizumab is combined with Imdevimab.
Bavituximab The risk or severity of adverse effects can be increased when Bavituximab is combined with Imdevimab.
CR002 The risk or severity of adverse effects can be increased when CR002 is combined with Imdevimab.
Rozrolimupab The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Imdevimab.
Hepatitis B immune globulin The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Imdevimab.
Girentuximab The risk or severity of adverse effects can be increased when Girentuximab is combined with Imdevimab.
Obiltoxaximab The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Imdevimab.
XTL-001 The risk or severity of adverse effects can be increased when XTL-001 is combined with Imdevimab.
NAV 1800 The risk or severity of adverse effects can be increased when NAV 1800 is combined with Imdevimab.
Briakinumab The risk or severity of adverse effects can be increased when Briakinumab is combined with Imdevimab.
Otelixizumab The risk or severity of adverse effects can be increased when Otelixizumab is combined with Imdevimab.
AMG 108 The risk or severity of adverse effects can be increased when AMG 108 is combined with Imdevimab.
Iratumumab The risk or severity of adverse effects can be increased when Iratumumab is combined with Imdevimab.
Enokizumab The risk or severity of adverse effects can be increased when Enokizumab is combined with Imdevimab.
Ramucirumab The risk or severity of adverse effects can be increased when Ramucirumab is combined with Imdevimab.
Farletuzumab The risk or severity of adverse effects can be increased when Farletuzumab is combined with Imdevimab.
Veltuzumab The risk or severity of adverse effects can be increased when Veltuzumab is combined with Imdevimab.
Ustekinumab The risk or severity of adverse effects can be increased when Ustekinumab is combined with Imdevimab.
Trastuzumab emtansine The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Imdevimab.
PRO-542 The risk or severity of adverse effects can be increased when PRO-542 is combined with Imdevimab.
TNX-901 The risk or severity of adverse effects can be increased when TNX-901 is combined with Imdevimab.
Inotuzumab ozogamicin The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Imdevimab.
RI 624 The risk or severity of adverse effects can be increased when RI 624 is combined with Imdevimab.
Stamulumab The risk or severity of adverse effects can be increased when MYO-029 is combined with Imdevimab.
CT-011 The risk or severity of adverse effects can be increased when CT-011 is combined with Imdevimab.
Leronlimab The risk or severity of adverse effects can be increased when Leronlimab is combined with Imdevimab.
Glembatumumab vedotin The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Imdevimab.
Olaratumab The risk or severity of adverse effects can be increased when Olaratumab is combined with Imdevimab.
IPH 2101 The risk or severity of adverse effects can be increased when IPH 2101 is combined with Imdevimab.
TB-402 The risk or severity of adverse effects can be increased when TB-402 is combined with Imdevimab.
Caplacizumab The risk or severity of adverse effects can be increased when Caplacizumab is combined with Imdevimab.
IMC-1C11 The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Imdevimab.
Eldelumab The risk or severity of adverse effects can be increased when Eldelumab is combined with Imdevimab.

Target Protein

Spike glycoprotein S

Referensi & Sumber

Synthesis reference: Hansen J, Baum A, Pascal KE, et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 2020;369(6506):1010-1014. doi:10.1126/science.abd0827
Artikel (PubMed)
  • PMID: 32540904
    Baum A, Fulton BO, Wloga E, Copin R, Pascal KE, Russo V, Giordano S, Lanza K, Negron N, Ni M, Wei Y, Atwal GS, Murphy AJ, Stahl N, Yancopoulos GD, Kyratsous CA: Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020 Aug 21;369(6506):1014-1018. doi: 10.1126/science.abd0831. Epub 2020 Jun 15.
  • PMID: 32540901
    Hansen J, Baum A, Pascal KE, Russo V, Giordano S, Wloga E, Fulton BO, Yan Y, Koon K, Patel K, Chung KM, Hermann A, Ullman E, Cruz J, Rafique A, Huang T, Fairhurst J, Libertiny C, Malbec M, Lee WY, Welsh R, Farr G, Pennington S, Deshpande D, Cheng J, Watty A, Bouffard P, Babb R, Levenkova N, Chen C, Zhang B, Romero Hernandez A, Saotome K, Zhou Y, Franklin M, Sivapalasingam S, Lye DC, Weston S, Logue J, Haupt R, Frieman M, Chen G, Olson W, Murphy AJ, Stahl N, Yancopoulos GD, Kyratsous CA: Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 2020 Aug 21;369(6506):1010-1014. doi: 10.1126/science.abd0827. Epub 2020 Jun 15.
  • PMID: 32807860
    Matthews DB: A cocktail of antibodies for COVID-19 therapy. Nat Rev Immunol. 2020 Oct;20(10):591. doi: 10.1038/s41577-020-00431-9.
  • PMID: 32203189
    Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, Zhou Y, Du L: Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol. 2020 Jun;17(6):613-620. doi: 10.1038/s41423-020-0400-4. Epub 2020 Mar 19.

Contoh Produk & Brand

Produk: 13 • International brands: 0
Produk
  • Casirivimab and Imdevimab
    Solution • - • Intravenous • Canada • Approved
  • Casirivimab and Imdevimab
    Solution • - • Intravenous • Canada • Approved
  • Casirivimab With Imdevimab
    Injection, solution, concentrate; Kit • - • Intravenous • US
  • Casirivimab With Imdevimab
    Injection, solution, concentrate; Kit • - • Intravenous • US
  • Imdevimab
    Injection, solution, concentrate • 300 mg/2.5mL • Intravenous • US
  • Imdevimab
    Injection, solution, concentrate • 1332 mg/11.1mL • Intravenous • US
  • Regen-cov
    Injection, solution, concentrate • - • Intravenous • US
  • Regen-cov
    Injection • - • Intravenous • US
Menampilkan 8 dari 13 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul